Ditchcarbon
  • Contact
  1. Organizations
  2. Exelixis, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

Exelixis, Inc.

Company website

Exelixis, Inc., a prominent biotechnology firm headquartered in the United States, has established itself as a leader in the oncology sector since its founding in 1994. With a focus on developing innovative cancer therapies, Exelixis operates primarily in North America and has made significant strides in advancing targeted treatments for various malignancies. The company’s flagship product, cabozantinib, exemplifies its commitment to precision medicine, offering unique mechanisms of action that address complex tumour biology. Exelixis has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position in the competitive biopharmaceutical landscape. With a robust pipeline and a dedication to improving patient outcomes, Exelixis continues to be a key player in the fight against cancer.

DitchCarbon Score

How does Exelixis, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Exelixis, Inc.'s score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.

39%

Let us know if this data was useful to you

Exelixis, Inc.'s reported carbon emissions

Exelixis, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Exelixis may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and climate action. However, without specific emissions data or reduction initiatives, it is challenging to assess Exelixis's position relative to its peers in terms of climate commitments.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Exelixis, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Exelixis, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Exelixis, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Alexion Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Byondis B.V.

NL
•
Research and development services (73)
Updated about 2 months ago

Pyxis Oncology, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Novimmune SA

CH
•
Research and development services (73)
Updated 14 days ago

Takeda

JP
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251028.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy